The clinical spectrum of the antiphospholipid syndrome (APS) encompasses additional manifestations other than thrombosis and pregnancy morbidity, which may potentially affect every organ and system. The pathophysiology of APS indeed cannot be explained exclusively by a prothrombotic state and the “extra-criteria” manifestations of the syndrome should be attributed to other mechanisms, such as inflammation, complement and platelet activation. In this case-series, we report patients with uncommon clinical APS presentations, to highlight relevant peculiarities of the syndrome, potentially paving the way for a further update of clinical as well as laboratory manifestations of this complex immunological condition.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
2.
RadinMUgolini-LopesMRSciasciaSAndradeD.Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management. Semin Arthritis Rheum2018;
48: 117–120.
3.
Lupi-HerreraESánchez-TorresGMarcushamerJMispiretaJHorwitzSEspino VelaJ.Clinical study of 107 cases. Am Heart J1977;
93: 94–103.
4.
HataANodaMMoriwakiRNumanoF.Angiographic findings of takayasu arteritis: new classification. Int J Cardiol1996;
54: S155–163.
5.
FukuiSHirotaSIwamotoNKarataHKawakamiA.Takayasu arteritis with antiphosphatidylserine/prothrombin antibody-positive antiphospholipid syndrome: case report and literature review. Medicine2015;
94: e2345.
6.
ChapmanJRandJHBreyRL, et al.
Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus2003;
12: 514–517.
7.
IslamMAAlamFWongKK.Comorbid association of antiphospholipid antibodies and migraine: a systematic review and meta-analysis. Autoimmun Rev2017;
16: 512–522.
8.
BucciTMenichelliDPignatelliPTriggianiMVioliFPastoriD.Relationship of antiphospholipid antibodies to risk of dementia: a systematic review. J Alzheimers Dis2019;
69: 561–576.
9.
IslamMAAlamFCavestroC, et al.
Antiphospholipid’ antibodies in epilepsy: a systematic review and meta-analysis. Autoimmun Rev2018;
17: 755–767.
10.
RicarteIFDutraLAAbrantesFF, et al.
Neurologic manifestations of antiphospholipid syndrome. Lupus2018;
27: 1404–1414.
11.
GrisJ-CNobileBBouvierS.Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res2015;
135: S56–59.
12.
CavinessJNGabelliniAKneeboneCSThompsonPDLeesAJMarsdenCD.Unusual focal dyskinesias: the ears, the shoulders, the back, and the abdomen. Mov Disord Mov Disord1994;
9: 531–538.
13.
PanzerJDalmauJ.Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol Curr Neurol2011;
24: 346–353.
14.
AlshubailiAAbou-Al-ShaarHSanthamoorthyPAttiaHBohlegaS.Ultrasound-guided botulinum toxin a injection in the treatment of belly dancer’s dyskinesia. BMC Neurol2016;
16: 16.
Rodríguez-GarcíaVIoannouYFernández-NebroAIsenbergDAGilesIP.Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology2015;
54: 2042–2050.
19.
RadinMFoddaiSGCecchiI, et al.
Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost2020;
120: 592–598.
20.
HoxhaAMattiaETonelloMGravaCPengoVRuffattiA.Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med2017;
55: 890–898.
21.
CerveraRBoffaM-CKhamashtaMAHughesGV.The euro-phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus2009;
18: 889–893.
22.
MehdiAASaltiIUthmanI.Antiphospholipid syndrome: endocrinologic manifestations and organ involvement. Semin Thromb Hemost2011;
37: 49–57.
23.
EspinosaGCerveraRFontJAshersonRA.Adrenal involvement in the antiphospholipid syndrome. Lupus2003;
12: 569–572.
24.
AshersonRACerveraRde GrootPG, Catastrophic Antiphospholipid Syndrome Registry Project Groupet al.
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus2003;
12: 530–534.
25.
StarakisIMazokopakisESiagrisDLiossisSKaratzaCAntonopoulosA.Catastrophic antiphospholipid syndrome presented with severe hypertension, adult respiratory distress syndrome and unilateral adrenal haemorrhagic infarction. Rheumatol Int2007;
27: 781–783.
26.
Galve-de RochemonteixBKobayashiTRosnobletC, et al.
Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells. Arterioscler Thromb Vasc Biol2000;
20: 563–574.
27.
AlessandriCBombardieriMDi ProsperoL, et al.
Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. Clin Exp Immunol2005;
140: 173–180.
28.
RamonIMathianABachelotA, et al.
Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab2013;
98: 3179–3189.
29.
PresottoFFornasiniFBetterleCFederspilGRossatoM.Acute adrenal failure as the heralding symptom of primary antiphospholipid syndrome: report of a case and review of the literature. Eur J Endocrinol2005;
153: 507–514.
30.
De LaatBVan BerkelMUrbanusRT, et al.
Immune responses against domain I of ß2-glycoprotein I are driven by conformational changes: domain I of ß2-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum2011;
63: 3960–3968.
31.
SciasciaSRadinMCecchiI, et al.
Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. J Nephrol2020;
33: 757–762.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
